Please ensure Javascript is enabled for purposes of website accessibility

NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

By Eric Volkman – Oct 27, 2020 at 9:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

LY-CoV555, which was being tested in combination with Gilead Sciences' remdesivir, showed no evidence of benefiting hospitalized COVID-19 patients.

A phase 3 clinical trial of a potential COVID-19 antibody therapy developed by Eli Lilly (LLY -0.76%) has been halted permanently, the company reported Monday night. No additional eligible participants will be dosed with LY-CoV555, also known as bamlanivimab. LY-CoV555 was being tested in combination with Gilead Sciences' recently FDA-approved remdesivir antiviral drug to treat the disease.

The stop was ordered by the government's National Institutes of Health (NIH) on the recommendation of an independent advisory committee. The NIH had been sponsoring the study.

The decision followed a temporary halt to the trial mandated by the NIH on Oct. 13 after a participant in the study experienced an adverse event.

A coronavirus colony.

Image source: Getty Images.

At the time, an Eli Lilly spokeswoman said the pause was effected "out of an abundance of caution" for safety issues. Further details were not provided.

As for the permanent halt, it is being mandated because NIH researchers concluded based on the already-collected trial data that Eli Lilly's antibody candidate probably wouldn't be effective in patients hospitalized with severe cases of COVID-19.

LY-CoV555 is a monoclonal antibody -- a synthetic protein that can be used to target certain antigens, and block their activities, flag them for attack by other aspects of the immune system, or deliver material to help defeat them.

Despite the NIH's permanent halt to the study, Eli Lilly pledged to continue other research being conducted with its candidate treatment, both as a monotherapy and in combination with another monoclonal antibody called etesevimab, to treat COVID-19.

While this news is disappointing, it should be noted that halts and cancellations of clinical trials for drug candidates are commonplace.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.